Inside the ICE House x Las Vegas: MindWave Innovations CEO Dr. Vin Menon
From Lake Las Vegas, Nevada, Dr. Vin Menon, CEO of MindWave Innovations, goes Inside the ICE House to discuss the growing adoption of digital asset treasury strategies by public companies. He explains how MindWave helps institutions establish Bitcoin-focused treasuries, generate yield, and navigate security and governance requirements. Menon also highlights the company’s merger with Apimeds Pharmaceuticals as a model for integrating digital assets into corporate balance sheets. He outlines how blockchain infrastructure and AI may converge to improve security, privacy, and operational efficiency across industries.
Article Link
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
MATAWAN, N.J. & LA JOLLA, Calif., May 05, 2026--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the "Inscobee Parties"), resolving all outstanding disputes arising from the APUS’ December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company’s previously disclosed $100 million PIPE financing, and the advancement of L
Article Link
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
MATAWAN, N.J. & SEOUL, South Korea, March 24, 2026--MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. ("APUS" or the "Company") (NYSE American: APUS), today announced that on March 20, 2026, Inscobee Inc. (KS:006490) and its wholly owned subsidiary Apimeds Inc. (together, "Inscobee"), in concert with certain other stockholders, filed an Amendment No. 2 to Schedule 13D with the Securities and Exchange Commission purporting to effect
Article Link
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
MATAWAN, N.J. & LA JOLLA, Calif., February 11, 2026--Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026.
Article Link
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
MATAWAN, N.J. & MOSCOW, Idaho, November 10, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds") today announced the expansion of its ai² Futures Lab™ program through a new collaboration with the University of Idaho College of Business and Economics, beginning in the Spring 2026 semester. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the h
Article Link
|